Abstract 2252P
Background
KRAS activating mutations are the most common oncogenic drivers and are correlated with radioresistance of multiple cancers including NSCLC and colorectal cancers. Multiple KRAS inhibitors were developed recently such as MRTX849 (Adagrasib,Mirati Therapeutics) showing promising clinical efficacy in early phase trials. However, only scarce data exploring the combination of radiotherapy (RT) and a KRAS inhibitor in KRASG12C mutated tumors are available. We explore the efficacy of the association between RT and MRTX1257, a selective and covalent KRASG12C inhibitor analogous to MRTX849, in animal models of cancer.
Methods
We assessed in vitro the efficacy of the combination MRTX1257 at various concentrations and different RT doses in CT26 WT and CT26 KRASG12C+/+ cell lines using clonogenic survival assays.We then explored the combination in LL2 NRAS-/- and WT cell lines. Subsequently, we explored the efficacy of combination MRTX1257 and RT in athymic nude mice bearing CT26 KRASG12C+/+ tumors and in immunocompetent BALB/c mice bearing subcutaneous CT26 WT or CT26 KRASG12C+/+ tumors.On day of randomization (D-1 before RT), D+1 and D+3 after RT, mice received oral MRTX1257 at 50 mg/kg dose. At D0, mice randomized into RT only and combination groups received 1x 6 Gy to the tumor. On D4 post RT, tumours were collected for IHC and flow cytometry analysis of the tumour microenvironment.
Results
MRTX1257 increased the cytotoxic effect of RT in different KRAS G12C mutated cell lines and murine tumors, but not in their KRAS G12C wild type counterparts. In vitro and in vivo radio-sensitizing effects were observed in a time and dose dependent manner. The use of RT and MRTX1257 in BALB/c mice bearing CT26 KRASG12C+/+ tumors resulted in a 20% cure rate. Tumor microenvironment analysis of murine CT26 KRASG12C+/+ tumors following RT and MRTX1257 showed an increase in conventional CD4+ T cells, DCs type 2 and inflammatory monocytes. Expression of PD-L1 was reduced within tumor and myeloid cells, illustrating TME polarization towards a pro-inflammatory phenotype following the combination.
Conclusions
This work constitutes a first step towards new combinatorial approaches involving RT and MRTX1257 in KRAS G12C mutated cancers, with the aim of providing new therapeutic strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Mirati Therapeutics.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2284P - Pre-clinical assessment of the therapeutic potential of a CD80-Fc-armed oncolytic virus (VSV-GP-CD80Fc)
Presenter: Andreas Ackermann
Session: Poster session 08
2285P - Lower response to COVID-19 booster dose vaccination on cancer patients comparing to healthy controls
Presenter: Pedro Cruz
Session: Poster session 08
2286P - COVID-19 vaccinations in cancer patients (pts): An individual participant data meta-analysis of the International Consortium on COVID vaccination in cancer
Presenter: Ha Mo Linh Le
Session: Poster session 08
2288P - Recolony-treating solid tumors with a bacteria-based approach
Presenter: Egle Katkeviciute
Session: Poster session 08
2289P - Determining anti-cancer efficacy of a reversible LSD1 inhibitor, EXS74539, in primary AML tissues with limited thrombocytopenic effects
Presenter: Christophe Boudesco
Session: Poster session 08
2291P - WU-NK-101, best in class memory-NK cell, has key features vital for adoptive cell therapy (ACT) in solid tumors (ST)
Presenter: John Muth
Session: Poster session 08
2292P - Prevalence of druggable EGFR genomic alterations in solid tumours other than lung cancer
Presenter: Tomohiro Kondo
Session: Poster session 08
2293P - Protumoral role of neutrophils and neutrophils extracellular traps (NETS) in non-metastatic gastroesophageal and rectal cancers
Presenter: Carlotta Catozzi
Session: Poster session 08
2294P - Whole genome sequencing to define the germline-somatic interaction in young-onset lung cancer
Presenter: Jaclyn LoPiccolo
Session: Poster session 08